首页|下调Yes相关蛋白1表达对食管癌细胞增殖与侵袭的影响

下调Yes相关蛋白1表达对食管癌细胞增殖与侵袭的影响

扫码查看
目的 探讨下调Yes相关蛋白1(YAP1)表达对食管癌细胞增殖与侵袭的影响。方法 实时荧光定量-聚合酶链反应(Real-time PCR)及蛋白质印迹法(Western blot)检测小干扰RNA(siRNA)YAP1-1、2、3的转染效果,将细胞分为control组和siRNA组。噻唑蓝(MTT)法检测细胞活力,细胞克隆形成实验检测细胞克隆能力,流式细胞术检测细胞凋亡,Tanswell实验检测细胞侵袭能力,Western blot检测B淋巴细胞瘤-2基因(bcl-2)、bcl-2相关蛋白X(bax)、p53、基质金属蛋白酶2(MMP-2)、MMP-9、c-Fos、c-Jun及p-c-Jun氨基末端激酶(JNK)表达。组间比较采用t检验。结果 siRNA-YAP1-1、2、3 组中 YAP1 mRNA 表达量低于 control 组(0。75±0。04、0。45±0。01、0。31±0。01比 1。00±0。08,t=5。621、6。324、6。897,P<0。05)。siRNA-YAP1-1、2、3 组中 YAP1 蛋白表达量低于control 组(0。62±0。03、0。34±0。01、0。20±0。01 比 0。94±0。07,t=5。904、6。561、6。438,P<0。05)。选择siRNA-YAP1-3作为后续实验研究对象。siRNA组细胞活力(0。35±0。01比0。58±0。04,t=5。761,P<0。05)、细胞克隆数目[(35。67±3。54)个 比(189。65±12。64)个,t=6。549,P<0。05]、细胞侵袭数目[(34。76±2。45)个 比(164。38±10。41)个,t=6。341,P<0。05]、bcl-2(0。89±0。07 比0。32±0。02,t=5。967,P<0。05)、MMP-2(0。92±0。07 比 0。37±0。02,t=6。214,P<0。05)及 MMP-9(1。09±0。08 比 0。38±0。02,t=6。287,P<0。05)蛋白表达量低于 control 组。siRNA 组细胞早期凋亡率[(21。57±1。68)%比(2。47±0。02)%,t=5。689,P<0。05]、晚期凋亡率[(17。42±1。36)%比(3。26±0。02)%,t=6。236,P<0。05)、bax(0。25±0。01 比 0。94±0。06,t=6。325,P<0。05)、p53(0。33±0。02 比 0。87±0。07,t=6。761,P<0。05)、c-Jun(0。36±0。02 比 1。05±0。08,t=6。698,P<0。05)、c-Fos(0。35±0。02 比 0。62±0。04,t=5。749,P<0。05)及 p-JNK(0。26±0。02 比 1。02±0。08,t=6。325,P<0。05]蛋白表达量高于control组。结论 下调YAP1表达可能通过激活JNK信号通路抑制EC109食管癌细胞的增殖与侵袭。
Effect of expression of Yes-associated protein 1 on proliferation and invasion in esophageal cancer cells
Objective To explore the effect of expression of Yes-associated protein 1(YAP1)on proliferation and invasion of esophageal cancer cells.Methods The transfection efficacy of small interfer-ing RNA(siRNA)YAP1-1,2,3 was detected by real time fluorescence quantitative polymerase chain re-action(Real-time PCR)and Western blotting.Cells were randomly divided into control and siRNA groups.Cell viability was measured by methyl thiazolyl tetrazolium(MTT)assay.Cell clone ability was detected by cell clone formation test.Cell apoptosis was detected by flow cytometry.Cell invasion ability was detected by Transwell method.The expression of B-lymphomatoma-2(bcl-2),bcl-2 related protein X(bax),p53,matrix metalloproteinase-2(MMP-2),MMP-9,c-Fos,c-Jun,and p-c-Jun N-terminal kinase(JNK)was de-tected by Western blotting.Inter group differences were analyzed by t-test.Results The expression of YAP1 mRNA in siRNA YAP1-1,2,3 groups was lower than that in the control group(0.75±0.04,0.45±0.01,0.31±0.01 vs.1.00±0.08,t=5.621,6.324,6.897,P<0.05).The expression level of YAP1 in siRNA YAP1-1,2,3 groups was lower than that in the control group(0.62±0.03,0.34±0.01,0.20±0.01 vs.0.94±0.07,t=5.904,6.561,6.438,P<0.05).Therefore,siRNA-YAP1-3 was select-ed as the subsequent experimental research object in this experiment.Cell viability(0.35±0.01 vs.0.58±0.04,t=5.761,P<0.05),cell clone number[(35.67±3.54)cells vs.(189.65±12.64)cells,t=6.549,P<0.05],cell invasion number[(34.76±2.45)cells vs.(164.38±10.41)cells,t=6.341,P<0.05],the expression of bcl-2(0.89±0.07 vs.0.32±0.02,t=5.967,P<0.05),MMP-2(0.92±0.07 vs.0.37±0.02,t=6.214,P<0.05)and MMP-9(1.09±0.08 vs.0.38±0.02,t=6.287,P<0.05)in the siRNA group were significantly reduced as compared with those in the control group.Cell early apoptosis rate[(21.57±1.68)%vs.(2.47±0.02)%,t=5.689,P<0.05],late apoptosis rate[(17.42±1.36)%vs.(3.26±0.02)%,t=6.236,P<0.05],the expression of bax(0.25±0.01 vs.0.94±0.06,t=6.325,P<0.05),p53(0.33±0.02 vs.0.87±0.07,t=6.761,P<0.05),c-Jun(0.36±0.02 vs.1.05±0.08,t=6.698,P<0.05),c-Fos(0.35±0.02 vs.0.62±0.04,t=5.749,P<0.05)and p-JNK(0.26±0.02 vs.1.02±0.08,t=6.325,P<0.05)in the siRNA group were sig-nificantly increased as compared with those in the control group.Conclusion Down-regulation of the YAP1 expression might inhibit the proliferation and invasion of esophageal cancer cell EC109 by activating the JNK signaling pathway.

Esophageal cancerYes-associated protein 1C-Jun N-terminal kinaseProlif-erationInvasion

肖华卫、张钊、刘磊

展开 >

烟台市烟台山医院肿瘤内科,烟台 264000

首都医科大学附属北京安贞医院普外科,北京 100029

食管癌 Yes相关蛋白1 c-Jun氨基末端激酶 增殖 侵袭

2024

中华实验外科杂志
中华医学会

中华实验外科杂志

CSTPCD
影响因子:0.759
ISSN:1001-9030
年,卷(期):2024.41(8)